Dihydroergotamine mesilate intranasal - Paratek Pharmaceuticals

Drug Profile

Dihydroergotamine mesilate intranasal - Paratek Pharmaceuticals

Alternative Names: STS-101; TO-2070

Latest Information Update: 01 Nov 2014

Price : $50

At a glance

  • Originator Transcept Pharmaceuticals Inc
  • Developer Paratek Pharmaceuticals; Shin Nippon Biomedical Laboratories
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Migraine

Most Recent Events

  • 30 Oct 2014 Transcept Pharmaceuticals Inc merged into Paratek Pharmaceuticals and is now called Paratek Pharmaceuticals
  • 25 Sep 2013 Dihydroergotamine mesilate intranasal (TO 2070) licensed to Shin Nippon Biomedical Laboratories worldwide ,
  • 25 Sep 2013 Preclinical trials in Migraine in USA (Intranasal) before Sep 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top